Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
High-yield, low-beta value plays for buy-and-hold investors
08:34am, Tuesday, 14'th Nov 2023
With risk omnipresent in the market and more reason than 1 to fear a recession, value, yield, and beta are more critical for successful investing than ever. If nothing else, volatility should be expec
Debt-Fueled Buybacks: 3 Stocks Undeterred by Rising Rates
11:36am, Monday, 13'th Nov 2023
Bloomberg published an article in early November about RTX Corp. (NYSE: RTX ) selling $6 billion in investment-grade bonds over various durations to help repay a short-term loan it got to cover its $1
Bristol-Myers Squibb Company (BMY) Management Presents at 2023 UBS BioPharma Conference (Transcript)
06:47am, Sunday, 12'th Nov 2023
Bristol-Myers Squibb Company (NYSE:BMY ) 2023 UBS BioPharma Conference Transcript November 8, 2023 8:00 AM ET Executives Lynelle Hoch - Head, Cell Therapy Analysts Trung Huynh - UBS Trung Huynh Okay.
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
07:25am, Saturday, 11'th Nov 2023
Merck and Bristol Myers Squibb are developing antibody-drug conjugates. Both are acquiring biotechs and assets to beef up their pipelines.
Is Bristol Myers Squibb Stock Undervalued At $50?
08:00am, Friday, 10'th Nov 2023
Bristol Myers Squibb (NYSE: BMY) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is
Fortunes Can Be Made With Bristol-Myers Squibb
01:51pm, Thursday, 09'th Nov 2023
Since early July, Bristol-Myers Squibb Co.'s (BMY, Financial) share price has been under downward pressure due, in part, to growing concerns among financial market participants about the ability of it
3 No-Brainer Stocks to Buy With $500 Right Now
05:21am, Wednesday, 08'th Nov 2023
The major stock indexes have bounced back and forth between bull and bear markets since the start of the decade. Most online brokerages have done away with investment-related barriers to entry (e.g.
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
09:47am, Monday, 06'th Nov 2023
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
5 Relatively Secure And Cheap Dividend Stocks To Invest In - November 2023
09:00am, Saturday, 04'th Nov 2023
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
Investor patience tested as pharmaceutical stocks take a tumble
06:07am, Wednesday, 01'st Nov 2023
The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor
Bristol Myers Squibb Revenue Falls on Generic Competition for Key Drug
04:55pm, Thursday, 26'th Oct 2023
Shares of Bristol Myers Squibb (BMY) fell Thursday after the company reported that sales of the drug maker's popular Revlimid blood cancer treatment plunged due to competition from generics.
Q3 GDP +4.9%, Earnings Beats for UPS, Bristol Myers and Honeywell
12:02pm, Thursday, 26'th Oct 2023
In the preliminary Q3 GDP print, consumer spending jumped to +4.0% while private domestic investment roared ahead +8.4%.
Bristol Myers Squibb (BMY) Surpasses Q3 Earnings and Revenue Estimates
09:48am, Thursday, 26'th Oct 2023
Bristol Myers Squibb (BMY) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.99 per share a year ago.
Bristol-Myers Squibb earnings top estimates
07:08am, Thursday, 26'th Oct 2023
Bristol-Myers Squibb Co. BMY, +0.87% on Thursday posted net income of $1.928 billion, or 93 cents a share, for the third quarter, up from $1.606 billion, or 75 cents a share, in the year-earlier perio
Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
07:05am, Thursday, 26'th Oct 2023
Bristol Myers Squibb's revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Revlimid.
